|
US6710174B2
(en)
|
2001-09-13 |
2004-03-23 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of vascular endothelial growth factor receptor-1 expression
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US6833349B2
(en)
*
|
1999-06-08 |
2004-12-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating inflammatory skin diseases
|
|
US7396664B2
(en)
|
1999-06-08 |
2008-07-08 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
CA2435503C
(en)
|
2001-01-19 |
2011-02-22 |
Ludwig Institute For Cancer Research |
Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
|
|
US6734017B2
(en)
|
2001-09-28 |
2004-05-11 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of vascular endothelial growth factor receptor-2 expression
|
|
US8183350B2
(en)
|
2002-05-04 |
2012-05-22 |
Acorda Therapeutics, Inc. |
Compositions and methods for promoting neuronal outgrowth
|
|
WO2004087206A2
(en)
|
2003-03-28 |
2004-10-14 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating diabetes by blocking vegf-mediated activity
|
|
EP3211084B1
(en)
|
2003-05-16 |
2019-03-27 |
Acorda Therapeutics, Inc. |
Proteoglycan degrading mutants for treatment of cns
|
|
US7959914B2
(en)
|
2003-05-16 |
2011-06-14 |
Acorda Therapeutics, Inc. |
Methods of reducing extravasation of inflammatory cells
|
|
AU2004247025B8
(en)
*
|
2003-05-16 |
2011-06-30 |
Acorda Therapeutics, Inc. |
Fusion proteins for the treatment of CNS
|
|
CA2519835A1
(en)
*
|
2003-05-28 |
2004-12-09 |
Regeneron Pharmaceuticals, Inc. |
Method of treating corneal transplant rejection
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
WO2004110490A2
(en)
*
|
2003-06-06 |
2004-12-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for tumor regression
|
|
US7399612B2
(en)
|
2003-06-30 |
2008-07-15 |
Regeneron Pharmaceuticals, Inc. |
VEGF-binding fusion proteins and nucleic acids encoding the same
|
|
AR046510A1
(es)
*
|
2003-07-25 |
2005-12-14 |
Regeneron Pharma |
Composicion de un antagonista de vegf y un agente anti-proliferativo
|
|
WO2005016369A1
(en)
*
|
2003-08-06 |
2005-02-24 |
Regeneron Pharmaceuticals, Inc. |
Use of a vegf antagonist in combination with radiation therapy
|
|
MXPA06013345A
(es)
|
2004-05-18 |
2008-10-31 |
Acorda Therapeutics Inc |
Metodos para purificar condrointinasa y sus formulaciones estables.
|
|
EP1767546B1
(en)
|
2004-06-08 |
2012-03-07 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Angiogenesis-inhibiting chimeric protein and the use
|
|
CA2567686A1
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
|
MXPA06014689A
(es)
*
|
2004-06-18 |
2008-03-11 |
Regeneron Pharma |
Inhibidores del vegf para el tratamiento de efusion pleural maligna.
|
|
AU2005267741A1
(en)
*
|
2004-07-30 |
2006-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating type I diabetes by blocking VEGF-mediated activity
|
|
PT2229956E
(pt)
*
|
2004-09-13 |
2013-07-31 |
Genzyme Corp |
Contruções multiméricas
|
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
|
US7303748B2
(en)
|
2005-02-02 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a VEGF inhibitor
|
|
ES2633574T3
(es)
|
2005-03-25 |
2017-09-22 |
Regeneron Pharmaceuticals, Inc. |
Formulaciones de antagonistas de VEGF
|
|
JP5189985B2
(ja)
|
2005-09-26 |
2013-04-24 |
アコーダ セラピューティクス、インク． |
コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
|
|
CA2630839C
(en)
†
|
2005-12-16 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with dll4 antagonists
|
|
FR2895258B1
(fr)
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
|
US8216575B2
(en)
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
|
CA2654510C
(en)
|
2006-06-16 |
2015-03-17 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
DK2066694T3
(en)
|
2006-09-29 |
2016-02-08 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
|
CA3009034C
(en)
|
2006-10-10 |
2020-08-18 |
Acorda Therapeutics, Inc. |
Compositions and methods of using chondroitinase abci mutants
|
|
FR2918279B1
(fr)
*
|
2007-07-05 |
2010-10-22 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
|
|
CN101575379B
(zh)
*
|
2008-05-09 |
2012-05-30 |
上海抗体药物国家工程研究中心有限公司 |
可溶性vegfr双功能融合受体、其制备方法及用途
|
|
BRPI0921469B1
(pt)
|
2008-11-03 |
2022-01-18 |
Molecular Partners Ag |
Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
|
|
CN101838329A
(zh)
*
|
2009-03-18 |
2010-09-22 |
嘉和生物药业有限公司 |
抗血管新生融合蛋白
|
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
|
AR081361A1
(es)
|
2010-04-30 |
2012-08-29 |
Molecular Partners Ag |
Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
|
|
EP3327032A1
(en)
|
2010-08-06 |
2018-05-30 |
Genzyme Corporation |
Vegf antagonist compositions and uses thereof
|
|
WO2012093704A1
(ja)
*
|
2011-01-07 |
2012-07-12 |
中外製薬株式会社 |
抗体の物性を改善させる方法
|
|
KR20190049934A
(ko)
|
2011-01-13 |
2019-05-09 |
리제너론 파아마슈티컬스, 인크. |
혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
|
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
|
KR101397088B1
(ko)
|
2011-06-10 |
2014-05-19 |
강원대학교산학협력단 |
암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
|
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
|
ES2651521T3
(es)
*
|
2011-12-01 |
2018-01-26 |
Innovent Biologics, Inc. |
Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
|
|
CN103304668B
(zh)
*
|
2012-03-12 |
2015-10-28 |
江苏健德生物药业有限公司 |
Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
|
|
ES2753135T3
(es)
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
|
WO2014006113A1
(en)
|
2012-07-03 |
2014-01-09 |
Sanofi |
Method of treating cancer by effective amounts of aflibercept
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
RS60026B1
(sr)
|
2013-02-18 |
2020-04-30 |
Vegenics Pty Ltd |
Molekuli koji vezuju ligande i njihove upotrebe
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
CN104193828B
(zh)
*
|
2013-09-12 |
2017-04-05 |
北京韩美药品有限公司 |
同时阻断her2和vegfr信号通路的重组融合蛋白
|
|
PT3065761T
(pt)
|
2013-11-05 |
2020-02-21 |
Allergan Inc |
Método de tratamento de condições oculares com um darpin anti-vegf
|
|
CN106456757A
(zh)
|
2014-05-12 |
2017-02-22 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
EA035674B1
(ru)
|
2014-07-18 |
2020-07-24 |
Санофи |
Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
|
|
JP2016036322A
(ja)
*
|
2014-08-11 |
2016-03-22 |
日本化薬株式会社 |
血管新生因子と結合するキメラタンパク質
|
|
CN114306575A
(zh)
|
2014-12-11 |
2022-04-12 |
拜耳医药保健有限责任公司 |
具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
|
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
|
TWI870789B
(zh)
|
2015-08-04 |
2025-01-21 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
|
WO2017046140A1
(en)
|
2015-09-18 |
2017-03-23 |
Bayer Pharma Aktiengesellschaft |
Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
|
|
KR101936049B1
(ko)
|
2015-10-15 |
2019-01-08 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 생산방법
|
|
WO2017065559A1
(ko)
|
2015-10-15 |
2017-04-20 |
(주)알테오젠 |
Igg fc 도메인을 가지는 융합 단백질의 생산방법
|
|
CN108290004A
(zh)
|
2015-11-18 |
2018-07-17 |
福尔密孔股份公司 |
含有vegf拮抗剂的预填充塑料注射器
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
WO2018218013A2
(en)
|
2017-05-24 |
2018-11-29 |
Sio2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
EP3377100B1
(en)
|
2015-11-18 |
2025-02-26 |
Formycon AG |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
WO2017084616A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
|
WO2017096031A1
(en)
|
2015-12-03 |
2017-06-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
|
|
US10576128B2
(en)
|
2016-01-26 |
2020-03-03 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
JPWO2018070390A1
(ja)
|
2016-10-12 |
2019-08-22 |
第一三共株式会社 |
抗ｒｏｂｏ４抗体と他剤を含む組成物
|
|
JP7116059B2
(ja)
|
2016-11-21 |
2022-08-09 |
ジャスト－エヴォテック バイオロジックス、インコーポレイテッド |
アフリベルセプト製剤及びその使用
|
|
EP3630043A1
(en)
|
2017-05-24 |
2020-04-08 |
Formycon AG |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
EP3668985B1
(en)
|
2017-08-17 |
2021-06-16 |
Just-Evotec Biologics, Inc. |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
|
MY202872A
(en)
|
2017-11-20 |
2024-05-28 |
Just Evotec Biologics Inc |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
|
CN111770999A
(zh)
*
|
2017-11-27 |
2020-10-13 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和用于抑制血管生成的应用
|
|
HUE059827T2
(hu)
*
|
2017-11-30 |
2023-01-28 |
Regeneron Pharma |
VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
|
|
IL319165A
(en)
*
|
2017-12-13 |
2025-04-01 |
Regeneron Pharma |
Apparatus and methods for managing support of a chromatography column substrate and related methods
|
|
WO2019124946A1
(ko)
|
2017-12-22 |
2019-06-27 |
삼성바이오에피스 주식회사 |
Vegf 길항제를 포함하는 액상 조성물
|
|
AU2019212622B2
(en)
|
2018-01-26 |
2024-05-23 |
The Regents Of The University Of California |
Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
|
|
DK4364724T3
(da)
|
2018-05-10 |
2025-12-22 |
Regeneron Pharma |
Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
|
|
TW202016125A
(zh)
*
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
|
WO2020229584A1
(en)
|
2019-05-16 |
2020-11-19 |
Formycon Ag |
Method for reducing methionine oxidation in recombinant proteins
|
|
TWI904098B
(zh)
|
2019-09-03 |
2025-11-11 |
美商安進公司 |
用於藥物遞送之注入裝置及用於注入裝置之包裝物
|
|
MX2022002980A
(es)
|
2019-09-16 |
2022-04-06 |
Amgen Inc |
Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
BR112022010113A2
(pt)
|
2019-11-25 |
2022-09-06 |
Univ California |
Inibidores de vegf de longa ação para neovascularização intraocular
|
|
SG11202110968VA
(en)
|
2019-12-06 |
2021-10-28 |
Regeneron Pharma |
Anti-vegf protein compositions and methods for producing the same
|
|
IL293286A
(en)
|
2019-12-06 |
2022-07-01 |
Regeneron Pharma |
vegf mini-traps and methods of using them
|
|
WO2021173603A1
(en)
|
2020-02-24 |
2021-09-02 |
Amgen Inc. |
Containers and systems for use during external sterilization of drug delivery devices
|
|
AU2021268026A1
(en)
|
2020-05-08 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
EP4438629A1
(en)
|
2021-11-24 |
2024-10-02 |
Suzhou Light Ferry Biomed. Co., Ltd |
Multispecific ligand binding molecule and application thereof
|
|
CN119677771A
(zh)
|
2022-08-02 |
2025-03-21 |
帕诺洛斯生物科技有限公司 |
经修饰的融合蛋白及其用途
|
|
TW202412840A
(zh)
|
2022-09-16 |
2024-04-01 |
大陸商齊魯製藥有限公司 |
一種穩定的高濃度自緩衝藥物組合物
|
|
AU2024322540A1
(en)
|
2023-08-04 |
2026-03-05 |
Panolos Bioscience, Inc. |
Conjugate of modified fusion protein and scfv, and use thereof
|
|
WO2025213011A1
(en)
|
2024-04-05 |
2025-10-09 |
Amgen Inc. |
Method of assessing stopper movement in a drug delivery device
|